Linking Pharma Manufacturing: CDMOs, Blockchain & Distributed Ledger Technologies (DLT)

June 26, 2019

The term blockchain is most often associated with cryptocurrencies such as Bitcoin, but the technology and its implications could have a more far-reaching impact on other industries including pharmaceutical manufacturing. Contract drug manufacturing organizations (CDMOs) and pharmaceutical developers could realize tangible benefits by implementing a variant of blockchain termed “Distributed Ledger Technology” (DLT).

Spotlight

SAJA Pharmaceuticals

SAJA is a joint venture between the premier Saudi healthcare company, Tamer, the Saudi partner, the (SA) in SAJA and two of the leading Japanese pharmaceutical companies, Daiichi Sankyo Co., Ltd. and Astellas Pharma Inc., the Japanese partners, the (JA) in SAJA. Both companies are major players in the Japanese healthcare sector, each with an impressive portfolio of ethical medicines.

OTHER WHITEPAPERS
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

Securing the modern pharmaceutical supply chain

whitePaper | April 22, 2022

Members of the Health-ISAC community have produced a security framework for the pharmaceutical supply chain comprising this CISO guide.

Read More
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More
news image

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More
news image

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Read More
news image

National Council for Prescription Drug Programs

whitePaper | May 12, 2022

This document is Copyright © 2022 by the National Council for Prescription Drug Programs (NCPDP). It may be freely redistributed in its entirety provided this copyright notice is not removed.

Read More

Spotlight

SAJA Pharmaceuticals

SAJA is a joint venture between the premier Saudi healthcare company, Tamer, the Saudi partner, the (SA) in SAJA and two of the leading Japanese pharmaceutical companies, Daiichi Sankyo Co., Ltd. and Astellas Pharma Inc., the Japanese partners, the (JA) in SAJA. Both companies are major players in the Japanese healthcare sector, each with an impressive portfolio of ethical medicines.

Events